Jubilant Pharmova Ltd.
NSE: JUBLPHARMA · Pharmaceuticals
Snapshot
Unlock Jubilant Pharmova Ltd.'s vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Jubilant Pharmova Limited is an integrated pharmaceutical company operating across pharmaceuticals, contract research, and proprietary novel drug development. Its portfolio includes allergy therapy products, sterile injectables, radiopharmaceuticals, and collaborative research services for global innovators.
Business Model
The company generates revenue through the manufacturing and supply of pharmaceutical products, contract research services, and the operation of a network of radio pharmacies in the United States. It leverages its integrated capabilities to serve both commercial markets and pharmaceutical innovators.
- US Radio Pharmacy Network:48 locations
Growth Outlook
Growth is driven by the expansion of its contract research and development services and the ongoing development of proprietary novel drugs in oncology and auto-immune disorders. The company continues to focus on its sterile injectables and radiopharmaceutical segments to maintain market presence.
Key Risks
- Regulatory Compliance. The company faces stringent regulatory oversight from global health authorities, where non-compliance could lead to manufacturing disruptions or product recalls.
- Geopolitical and Market Concentration. Significant reliance on the United States market for radiopharmaceuticals exposes the company to changes in US healthcare policy and pricing pressures.
- R&D Failure Risk. The proprietary novel drugs segment involves high-risk investments in clinical trials that may not result in commercially viable products.
- Supply Chain Volatility. Dependence on global supply chains for active pharmaceutical ingredients and raw materials makes the company vulnerable to logistics disruptions and price fluctuations.
Start your research today
Unlock AI insights, financials, peers and live data on Jubilant Pharmova Ltd. and 5,000+ companies — free.
Key Metrics
REVENUE
₹8,608 Cr
TTM · consolidated
NET PROFIT
₹351 Cr
TTM · consolidated
EPS
₹22.23
TTM · consolidated
RETURN ON EQUITY
5.3%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
6.5%
TTM · consolidated
P/E
45.0×
Q1 FY27 · consolidated
EV/EBITDA
14.6x
Q1 FY27 · consolidated
EBITDA MARGIN
15.0%
TTM · consolidated
NET PROFIT MARGIN
2.5%
Q1 FY27 · consolidated
DEBT TO EQUITY
0.5x
Q1 FY27 · consolidated
Peers · Pharmaceuticals
| Company | Mkt Cap | P/E (TTM) | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Jubilant Pharmova Ltd.JUBLPHARMA | ₹16,852 Cr | 45.0× | 14.55 | 16.3% | 15.0% | 5.3% | 6.5% | -10.2% |
Cohance Lifesciences Ltd.COHANCE | ₹17,654 Cr | 162.3× | 51.03 | 41.2% | 16.3% | 2.1% | 3.5% | -48.2% |
Eris Lifesciences Ltd.ERIS | ₹17,597 Cr | 25.3× | 17.31 | 9.7% | 35.5% | 19.7% | 15.5% | -26.8% |
AstraZenca Pharma India Ltd.ASTRAZEN | ₹16,765 Cr | 88.9× | 63.65 | 31.1% | 10.5% | 20.6% | 25.7% | -34.6% |
Alembic Pharmaceuticals Ltd.APLLTD | ₹16,598 Cr | 23.1× | 14.42 | 14.1% | 15.8% | 12.7% | 14.3% | -9.8% |
Concord Biotech Ltd.CONCORDBIO | ₹16,323 Cr | 52.7× | 37.08 | -6.7% | 39.7% | 14.2% | 18.5% | -15.9% |
As of Q1 FY27
Financials
Jubilant Pharmova Ltd.
NSE: JUBLPHARMA · Pharmaceuticals
Snapshot
Unlock Jubilant Pharmova Ltd.'s vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Jubilant Pharmova Limited is an integrated pharmaceutical company operating across pharmaceuticals, contract research, and proprietary novel drug development. Its portfolio includes allergy therapy products, sterile injectables, radiopharmaceuticals, and collaborative research services for global innovators.
Business Model
The company generates revenue through the manufacturing and supply of pharmaceutical products, contract research services, and the operation of a network of radio pharmacies in the United States. It leverages its integrated capabilities to serve both commercial markets and pharmaceutical innovators.
- US Radio Pharmacy Network:48 locations
Growth Outlook
Growth is driven by the expansion of its contract research and development services and the ongoing development of proprietary novel drugs in oncology and auto-immune disorders. The company continues to focus on its sterile injectables and radiopharmaceutical segments to maintain market presence.
Key Risks
- Regulatory Compliance. The company faces stringent regulatory oversight from global health authorities, where non-compliance could lead to manufacturing disruptions or product recalls.
- Geopolitical and Market Concentration. Significant reliance on the United States market for radiopharmaceuticals exposes the company to changes in US healthcare policy and pricing pressures.
- R&D Failure Risk. The proprietary novel drugs segment involves high-risk investments in clinical trials that may not result in commercially viable products.
- Supply Chain Volatility. Dependence on global supply chains for active pharmaceutical ingredients and raw materials makes the company vulnerable to logistics disruptions and price fluctuations.
Start your research today
Unlock AI insights, financials, peers and live data on Jubilant Pharmova Ltd. and 5,000+ companies — free.
Key Metrics
REVENUE
₹8,608 Cr
TTM · consolidated
NET PROFIT
₹351 Cr
TTM · consolidated
EPS
₹22.23
TTM · consolidated
RETURN ON EQUITY
5.3%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
6.5%
TTM · consolidated
P/E
45.0x
Q1 FY27 · consolidated
EV/EBITDA
14.6x
Q1 FY27 · consolidated
EBITDA MARGIN
15.0%
TTM · consolidated
NET PROFIT MARGIN
2.5%
Q1 FY27 · consolidated
DEBT TO EQUITY
0.5x
Q1 FY27 · consolidated
Peers · Pharmaceuticals
As of Q1 FY27